Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Da Zen Theranostics Inc. is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, indicating that the company's current patent applications are being reviewed by different individuals. This split in examiner assignment can lead to varied prosecution timelines for the 2 pending office actions.
The prosecution is split across 2 distinct art units, which suggests a degree of technical diversity within the company's biotechnology focus. WELLS, LAUREN QUINLAN is the busiest examiner, holding 1 pending action. Since there are 2 distinct examiners, each is responsible for a portion of the workload. Practitioners should be prepared to handle prosecution in 2 distinct art units, which may have different average pendency rates or examination trends. The 1 pending action under WELLS, LAUREN QUINLAN represents a specific portion of the company's active office action responses.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +60.1% |
| RODRIGUEZ, RAYNA B | 1 | 33.5% | +19.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18123240 | Artemisinin Derivatives | WELLS, LAUREN QUINLAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18123240 | Artemisinin Derivatives | WELLS, LAUREN QUINLAN | — |
| 18076213 | Tumor Homing Statin Derivatives | RODRIGUEZ, RAYNA B | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18123240 | Artemisinin Derivatives | WELLS, LAUREN QUINLAN | 1622 | §103§112 | Non-Final OA | — | Pending | Mar 17, 2023 |
| 18076213 | Tumor Homing Statin Derivatives | RODRIGUEZ, RAYNA B | 1628 | §103DP | Non-Final OA | — | Pending | Dec 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDa Zen Theranostics Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Lauren Quinlan Wells has the most, with 1 of Da Zen Theranostics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.